TP53 is commonly mutated in small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) [74, 75] and non-Hodgkin lymphoma (NHL) [72] including DLBCL [76], FL [77], mantle cell lymphoma (MCL) [78], and BL [79], and TP53 mutations are associated with poor overall survival (OS) and progression-free survival (PFS). This evidence concerns the gene TP53 and mantle cell lymphoma.